Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement for the first to eighth batches of drugs, marking the first nationwide unified continuation of centralized procurement for chemical drugs [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is involved in the new round of continuation procurement organized by the state [1] - The continuation procurement includes the company’s products such as Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch) [1] Group 2: Market Impact - The selected products will be prioritized for use by medical institutions during the procurement period, ensuring the completion of the agreed procurement volume [1] - The selection in this continuation procurement reflects the stability and reliability of the company’s drug quality, which is expected to expand the sales scale of the selected products and increase market share [1] - This development is anticipated to strengthen the company’s competitiveness in the peptide pharmaceutical market and positively impact its operational growth [1]

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), has participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results, which will positively impact its market share and future performance [1]. Group 1: Procurement Participation - On February 9, 2026, the company participated in the national organized procurement for drugs with expired agreements [1]. - The procurement results are expected to be implemented by the end of March 2026, allowing provincial medical institutions to sign contracts with manufacturers based on the selected results [1]. Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1]. - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which will have a positive effect on its future operating performance [1].

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results [1] Group 1: Procurement Details - The company attended the national organized procurement for drugs with expired agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions beginning to sign procurement contracts based on the selected results [1] Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1] - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which may positively impact its future operating performance [1]

灵康药业公告称，2026年2月10日，公司控股股东灵康控股部分股份解除质押，数量为4965.96万股，占 其持有公司股份总数的14.62%，占公司总股本的6.89%。灵康控股直接及间接持有公司股份33965.28万 股，占公司总股本的47.09%。解除质押后，其剩余被质押股份数量为5400.00万股，占其所持股份比例 为15.90%，占公司总股本比例为7.49%。经确认，解除质押的股份暂无后续质押计划。 ...

班塞尔指出："以FDA已批准的疫苗作为对照进行流感疫苗申报，且该研究方案在启动前已与CBER讨 论并达成一致，对此申请进行全面审评本不应存在争议。"该公司为mRNA-1010提交的上市申请包含两 项后期研究，这些研究均达到了试验的主要目标。 Moderna去年曾表示，其mRNA-1010疫苗比葛兰素史克(GSK.US)已获批的流感疫苗有效性高出26.6%。 该公司称已要求与FDA举行会议，以明确后续路径。 这一进展发生在美国全面修订其长期实施的儿童免疫指导方针，并撤回对包括流感在内的六种传染病常 规疫苗接种建议的一个多月后。Moderna在今年早些接受采访时表示，由于美国官员对疫苗接种的反对 声浪日益高涨，公司不打算投资新的后期疫苗临床试验。当前FDA已批准的流感疫苗包括阿斯利康 (AZN.US)和赛诺菲(SNY.US)生产的产品。 Moderna去年撤回了其流感-新冠联合疫苗的上市申请，以等待其流感疫苗后期试验的有效性数据。目前 该疫苗正在欧盟、加拿大和澳大利亚接受审评，公司预计有望在2026年底或2027年初获得批准。 智通财经APP获悉，Moderna(MRNA.US)周二表示，美国食品药品监督管理局( ...

近日，专注于线粒体医学的生物制药企业——康诺生物制药股份有限公司（下称"康诺生物"）向港交所递交上市申请，引发市场关注。然而，根据其披露的 草本招股文件及专业分析，其上市之路并非坦途。尽管公司手握"抗衰老"与"创新药"两大热门概念，然而其申请文件中暴露出的法律合规问题、核心业务存 在的脆弱性以及信息披露不够深入，已然成为横亘在上市路上的最大"拦路虎"。 越界物业与模糊的历史 在所有问题中，物业与土地使用的合规性问题是悬在康诺生物头顶最危险的"达摩克利斯之剑"。 招股书坦承，公司部分生产经营所用物业存在 "越界使用" ，即建筑物超出了土地使用权证的范围。在中国严格的土地管理法规下，这属于明确的违法违规 行为，可能导致行政处罚、责令拆除，甚至影响《药品生产许可证》的续期。 尽管公司声称已获得相关主管部门的确认，但根据土地使用权披露的规范要求，公司应在招股书中提供具有法律效力的政府批文或正式豁免文件，以证明其 土地使用权的合规性。这种轻描淡写的表述，试图将重大法律风险包装为已解决的"历史问题"，恰恰是监管机构与投资者最为警惕的信号。联交所极有可能 要求其提供省级以上自然资源和住建部门出具的明确确权意见，以及独立法律 ...

根据合作协议，双方将结合英矽智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰 富的研发团队和对疾病领域的深度认知，共同推进不少于2个研发项目的合作开发。同时，英矽智能有 望就每个项目获得最高达数千万港元的研发费用支持。此次合作将充分发挥双方在药物研发、临床开发 及商业化全周期的协同优势，通过资源整合与技术互补，加速高潜力创新药物的研发与转化。英矽智能 将依托其Pharma.AI平台以及在靶点发现、小分子设计与优化等领域的技术能力，推动候选分子的高效 筛选与验证；康哲药业则凭借其在临床开发策略制定、注册申报路径规划、临床试验组织实施以及商业 化推广方面的丰富经验和成熟网络，推动项目从临床前过渡至临床及上市阶段。 近日，英矽智能发布公告称，与康哲药业控股有限公司在中枢神经系统及自身免疫疾病领域的多个项目 上达成一系列由AI赋能的创新药物研发合作。 ...

Core Viewpoint - Recently, Harbin Pharmaceutical Group Co., Ltd. (stock code: 600664) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, received a "Drug Supplement Application Approval Notice" from the National Medical Products Administration for injectable Cefotaxime Sodium, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The drug is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, and gynecological infections [1] - As of the announcement date, there are a total of 239 production approvals for injectable Cefotaxime Sodium in China, with 37 manufacturers having passed the consistency evaluation [1] - The domestic sales revenue for the drug is projected to be 1.55 billion yuan in 2024, with 889 million yuan expected in the first three quarters of 2025 [1] Group 2 - The company has invested approximately 8.1573 million yuan in research and development for the consistency evaluation project of this drug [1]

Core Viewpoint - QianYuan Pharmaceutical (300254) announced that its largest shareholder, Zhao Qun, has had 15.78 million shares frozen by the People's Court of Xinhua District, Shijiazhuang City, accounting for 100% of his holdings and 6.16% of the company's total share capital [1] Summary by Category - Shareholder Action - Zhao Qun's shares were frozen due to a pre-litigation preservation request filed by Cao Xitong with the People's Court of Shijiazhuang Xinhua District [1] - Financial Implications - The court's ruling involves a frozen amount of 50 million yuan [1]

Group 1: Company Project Progress - The company has over 30 research and development projects, with global patent expirations concentrated between 2028 and 2033. Some products, such as Vabigatran and Rosuvastatin, are already in the registration submission stage [2] - The company plans to continuously add new product projects each year to create a tiered product structure. Additionally, its affiliate, Boya Biotech, focuses on high-difficulty specialty formulations, which may lead to business synergies [2] Group 2: Business Development - On February 4, 2026, the company announced that the raw material for Edoxaban passed the approval of the National Medical Products Administration (NMPA), which is expected to boost sales in the domestic market and synchronize with international market expansion [3] - The company is implementing a "first generic, one supply" strategy, with approved new products like Vildagliptin and Agomelatine set to join the domestic sales lineup and actively expand into emerging markets [3] Group 3: Business Status - Currently, domestic business revenue accounts for approximately 20% of total revenue. The company plans to bind with leading generic drug companies as main suppliers, with an average of 3-5 core customers per product, to further expand its domestic market share [4] - Seventeen technically mature new products are capable of global supply, and the company will rely on the early layout of the supply chain for products with upcoming patent expirations [4] Group 4: Company Situation - The company has recently obtained several invention patents, such as methods for catalyst regeneration, but has not disclosed specific timelines for industrialization [5] - As of the end of January 2026, there was a net outflow of main funds, but market sentiment changes should be observed in conjunction with subsequent performance and order fulfillment [5]